Pacer Advisors Inc. increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 155.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,460 shares of the company’s stock after acquiring an additional 5,760 shares during the quarter. Pacer Advisors Inc.’s holdings in Omnicell were worth $697,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in shares of Omnicell by 16.4% during the first quarter. Wellington Management Group LLP now owns 3,815,052 shares of the company’s stock worth $223,829,000 after purchasing an additional 537,452 shares during the last quarter. Norges Bank acquired a new stake in Omnicell in the 4th quarter worth about $22,291,000. Champlain Investment Partners LLC grew its holdings in Omnicell by 40.0% in the 1st quarter. Champlain Investment Partners LLC now owns 983,995 shares of the company’s stock valued at $57,731,000 after buying an additional 281,305 shares during the period. Rockefeller Capital Management L.P. increased its stake in shares of Omnicell by 698.2% during the 1st quarter. Rockefeller Capital Management L.P. now owns 272,768 shares of the company’s stock valued at $16,003,000 after acquiring an additional 238,593 shares during the last quarter. Finally, Granite Investment Partners LLC lifted its holdings in shares of Omnicell by 289.5% during the 1st quarter. Granite Investment Partners LLC now owns 309,855 shares of the company’s stock worth $18,179,000 after acquiring an additional 230,295 shares during the period. 99.18% of the stock is owned by hedge funds and other institutional investors.
Omnicell Trading Down 0.5 %
Shares of OMCL opened at $45.04 on Friday. Omnicell, Inc. has a 12 month low of $44.05 and a 12 month high of $91.99. The stock’s 50-day moving average is $58.17 and its two-hundred day moving average is $63.37. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.38 and a quick ratio of 2.03. The stock has a market cap of $2.04 billion, a PE ratio of -86.62, a P/E/G ratio of 6.53 and a beta of 0.84.
Analyst Ratings Changes
OMCL has been the subject of a number of recent analyst reports. KeyCorp lowered their target price on shares of Omnicell from $80.00 to $75.00 and set an “overweight” rating for the company in a report on Friday, August 4th. StockNews.com assumed coverage on Omnicell in a report on Thursday, August 17th. They set a “hold” rating for the company. Piper Sandler cut Omnicell from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $66.00 to $70.00 in a report on Wednesday, August 2nd. Wells Fargo & Company lowered their price target on Omnicell from $56.00 to $39.00 and set an “underweight” rating for the company in a research report on Tuesday. Finally, Benchmark restated a “buy” rating and issued a $88.00 price objective on shares of Omnicell in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $66.63.
Get Our Latest Research Report on OMCL
Omnicell Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
- Five stocks we like better than Omnicell
- Best Aerospace Stocks Investing
- CarMax Slides On Earnings Disappointment, Time To Celebrate?
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- The Next Stage Of Google’s Rally Just Started
- Space Investment: How to Invest in Space Exploration
- Can Investors Win the Race with Dividend Achiever Nike?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
